A Phase II, Multicenter, Single Arm Study to Determine the Efficacy of SBRT in Combination With Durvalumab Synchronous Platinum-Based Chemotherapy for the First-Line Treatment in Patients With Extensive Disease Small-Cell Lung Cancer (SCLC)
Latest Information Update: 04 Aug 2020
Price :
$35 *
At a glance
- Drugs Durvalumab (Primary) ; Carboplatin; Cisplatin; Etoposide
- Indications Small cell lung cancer
- Focus Therapeutic Use
- Acronyms CADMUS
- 04 Aug 2020 New trial record